Table 1

Characteristics of the 12 patients with systemic sclerosis (SSc) and adipose tissue harvest

Demographic
 Number of patients, sex12, all female
 Age (years)54.5±10.3 (34.0–68.0)
 Body mass index (kg/m2)22.0±2.1 (18.6–26.2)
Dominant hand
 Right-handed/left-handed10 (83.3%)/2 (16.7%)
Main causes of hand disability
 1. Vascular aspects (Raynaud's phenomenon)12 patients (100%)
 2. Skin fibrosis (sclerodactyly)11 patients (92%)
 3. Musculoskeletal aspects (joint synovitis)5 patients (42%)
Cardiovascular risk factors
 Tobacco0 (0.0%)
 Diabetes0 (0.0%)
 Arterial hypertension0 (0.0%)
Disease history
 Disease duration from diagnosis (years)9.9±7.0 (2.0–24.0)
 Early SSc disease <4 years3 (25%)
 History of Raynaud's phenomenon (years)14.3±7.7 (5.0–34.0)
 Systemic sclerosis cutaneous subclassification: limited/diffuse7 (58.3%)/5 (41.7%)
 Pulmonary arterial hypertension or previous renal crisis0 (0.0%)
Rodnan
 Global modified Rodnan skin score13.9±9.8 (3–32)
Gastrointestinal
 Gastrointestinal reflux9 (75%)
 Hypotonia of the inferior oesophagus sphincter (manometry)9/9 tested
Lung
 Total lung capacity <80%0 (0%)
 Lung capacity for carbon monoxide/alveolar ventilation <75%5 (41.7%)
 Fibrosis on high-resolution chest tomography (bronchiectasia and/or honeycombing)2 (16.7%)
Serology
 Anti-nuclear antibodies positive (indirect immunofluorescence on HEp2)12 (100%)
 Anti-topoisomerase 1 (Scl70) antibodies positive (ELIA)6 (50.0%)
 Anti-centromere antibodies positive (ELIA)4 (33.3%)
 Anti-SSA antibodies positive (ELIA)2 (16.7%)
Ongoing and previous systemic sclerosis medications
 Calcium-channel blockers6 ongoing (50.0%), 11 previously (91 7%)
 Bosentan2 ongoing (16.6%), 4 previously (33 3%)
 Prednisone <10 mg/day3 ongoing (25.0%)
 Methotrexate1 ongoing (8.3%)
 Iloprost infusion0 ongoing, 8 previously (66.7%)
Adipose tissue harvest and cell characterisation
 Amount of adipose tissue harvest (mL)181.3±50.8 (120–270)
 Number of total viable nucleated cells (×106)50.5±23.8 (16.7–92.6)
 % of cell viability88.0±4.8 (81.0–94.6)
 Number of viable nucleated cells injected into each finger (×106)3.76±1.85 (1.19–7.07)
 % of CFU-F3.7±1.9 (1.6–8.1)
 % of blood leucocytes (CD45 CD34− cells)49.1±18.0
 % of endothelial progenitor cells (CD34brightCD146dimCD45-)3.4±3.2
 % of circulating endothelial cells (CD34dimCD146brightCD45-)6.4±6.8
 % of stromal cells (CD45-CD34brightCD146-CD90+)36.0±14.5
 % of resident macrophages (CD45+CD14+CD34dim)5.1±2.3
  • Data are mean±SD (minimum and maximum) or n (%) of patients.